RxDoctor Payments Data

Mavany Tant, PA

Medical · Orlando, FLNPI 1457724403

Payments from drug & device makers

$7,164in general payments, 2019–2025

Across 281 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Myriad Genetic Laboratories, Inc.$998
  • Astellas Pharma US Inc$911
  • Sumitomo Pharma America, Inc.$683
  • Ferring Pharmaceuticals Inc.$489
  • Endo Pharmaceuticals Inc.$410
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$6,44790%
  • Education$71710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,164 in reported general payments places this provider in the 90th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$48,635
Medicare patients
229
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide52$749,590
OrgovyxRelugolix70$202,181
MyrbetriqMirabegron109$105,451
GemtesaVibegron60$61,546
Tamsulosin Hcl665$8,906
Alfuzosin Hcl ErAlfuzosin Hcl313$6,754
Tolterodine Tartrate ErTolterodine Tartrate55$6,018
Testosterone Cypionate128$5,847
Finasteride282$3,785
Oxybutynin Chloride ErOxybutynin Chloride91$3,616
Methenamine Hippurate43$3,485
Tadalafil20$3,334
NatestoTestosterone11$3,201
Bicalutamide19$2,313
Dutasteride79$2,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$911$855,040161 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$683$263,727130 claims
Acerus Pharmaceuticals CorporationNatesto$29$3,20111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,031 medical providers in Florida.

Other medical in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →